Loading
A phase 1/2 trial of Ivonescimab, Cadonilimab, Sintilimab in hepatocellular carcinoma, run by Akeso, now recruiting.
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06530251 by Akeso, with 280 participants planned, started 2024-09-24 and due to reach its primary completion in 2026-06. Interventions recorded: AK112, Cadonilimab, AK127, AK130, Sintilimab Injection. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Advanced hepatocellular carcinoma (BCLC C), Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Akeso, Ivonescimab.
Shares Cadonilimab, Akeso.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/